“One of the greatest things that I can do is to walk up to a patient who has cancer and to be able to say to them, ‘I’ve got some really good news.’ How I’m able to say that? It’s because of you, and what you do participating in Pelotonia.”

Dr. Michael Caligiuri

Director, OSU Comprehensive Cancer Center
CEO, James Cancer Hospital and Solove Research Institute

Our Impact

Since 2009, Pelotonia has raised over $106 million for innovative cancer research at The Ohio State University Comprehensive Cancer Center–James Cancer Hospital and Solove Research Institute.

Our Impact

Pelotonia dollars have funded a statewide initiative aimed at identifying those at high risk for colorectal, ovarian, and uterine cancer so they can seek preventative care.

Our Impact

Pelotonia dollars have supported the groundbreaking clinical trials of Ibrutinib, which is now FDA approved for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.


We have been able to spend several years focusing on why some instances of squamous cell carcinoma (skin cancer) become fatal. We are close to discovering what makes certain tumors in this cancer fatal for thousands of people each year. Our work has led to a point of great discovery, but we can do much more.

Amanda Ewart Toland, PhD



Fellowship Program

encourages promising students to pursue research with faculty mentors.


Idea Grants

provide seed money to teams of faculty researchers who are collecting data in order to apply for larger external grants.


Sophisticated equipment and technologies

aid cutting-edge research.


Recruitment and Retention

of the brightest minds in cancer research.

Year after year, through the dedication of our Riders, Virtual Riders, Volunteers, and Donors, Pelotonia continues to grow. 

Join us in making an impact.


Riders, Virtual Riders, Volunteers, and Donors Pursuing One Goal


Idea Grants Given to Researchers with Transformational Ideas


$11 million has funded 399 student fellowships at The Ohio State University


Senior Scientists Funded to Pursue Cutting-edge Research